Anne-Sophie Gille

Mrs. Anne-Sophie Gille

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
AGAnne-Sophie Gille
Anne-Sophie Gille
CPCorinne Pondarré
Corinne Pondarré
JDJean-Hugues Dalle
Jean-Hugues Dalle
FBFrançoise Bernaudin
Françoise Bernaudin
CCCéline Chalas
Céline Chalas
VBVirginie Barraud-Lange
Virginie Barraud-Lange
In these two short reports, the authors approach the issue of whether hydroxyurea (HU) use in young males has major irreversible effects on sperm production. Joseph et al analyzed and compared sperm parameters in male patients with sickle cell disease (SCD) who were exposed or not exposed to HU before puberty. They report semen abnormalities in all patients but no differences between groups. Independently, Gille et al provide evidence for the lack of in vivo HU-related decreases in the spermatogonial pool in biopsy specimens from young males with SCD but evidence for a negative effect of SCD itself. Together, these reports suggest that the use of HU in young males does not adversely affect fertility.

15 November 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LMLaetitia Mauge
Laetitia Mauge
AMArnaud Mejean
Arnaud Mejean
LFLaure Fournier
Laure Fournier
HPHelena Pereira
Helena Pereira
MEMarie-Christine Etienne-Grimaldi
Marie-Christine Etienne-Grimaldi
Stephane OudardStephane Oudard
Stephane Oudard
Purpose: The PREINSUT study characterized factors predictive of response to sunitinib given before planned nephrectomy in patients with metastatic renal cell carcinoma (mRCC). Experimental Design: This French multicenter, prospective, open-label, phase II trial (NCT00930345) included treatment-naïve patients with clear-cell mRCC. Patients received two cycles of sunitinib before nephrectomy. The primary objective was to evaluate the potential of circulating angiogenesis-related biomarkers measured before and on treatment for identifying responders based on primary renal tumor (PRT) size change. Secondary objectives were to evaluate the ability of biomarkers to predict progression-free survival (PFS) and overall survival (OS). Results: Thirty-two patients were enrolled. The median PFS was 4.5 months, and the median OS was 12.4 months. OS was significantly longer in responding patients (28.8 vs. 11.1 months; P = 0.03). Of 27 patients evaluable for PRT response, nine (33.3%) had a ≥10% decrease in PRT size. Baseline biomarkers significantly associated with outcome were endothelial progenitor cells (PRT response); vascular endothelial growth factor (VEGF)-A, stromal cell–derived factor-1 (SDF-1), soluble VEGF receptors (sVEGFR)1 and 2 (PFS); and SDF-1 and sVEGFR1 (OS). During treatment, changes in biomarkers associated with outcome were SDF-1 and platelet-derived growth factor (PDGF)-BB (PRT response), sVEGFR2 (PFS), and SDF-1 and sVEGFR1 (OS). There was no correlation between plasma sunitinib or its active metabolite steady-state trough concentrations and clinical outcome. Conclusion: Angiogenesis-related parameters that could reflect hypoxia seem to be associated with worse outcome in mRCC. As blood biomarkers are not subjected to tumor heterogeneity and allow longitudinal follow-up, circulating angiogenesis profile has a promising place in antiangiogenic therapy guidance. Clin Cancer Res; 1–9. ©2018 AACR.

Verified
Journal Article
Open access
PDF file
AGAnne-Sophie Gille
Anne-Sophie Gille
CLClémentine Lapoujade
Clémentine Lapoujade
JWJean-Philippe Wolf
Jean-Philippe Wolf
PFPierre Fouchet
Pierre Fouchet
VBVirginie Barraud-Lange
Virginie Barraud-Lange
Ongoing progress in genomic technologies offers exciting tools that can help to resolve transcriptome and genome-wide DNA modifications at single-cell resolution. These methods can be used to characterize individual cells within complex tissue organizations and to highlight various molecular interactions. Here, we will discuss recent advances in the definition of spermatogonial stem cells (SSC) and their progenitors in humans using the single-cell transcriptome sequencing (scRNAseq) approach. Exploration of gene expression patterns allows one to investigate stem cell heterogeneity. It leads to tracing the spermatogenic developmental process and its underlying biology, which is highly influenced by the microenvironment. scRNAseq already represents a new diagnostic tool for the personalized investigation of male infertility. One may hope that a better understanding of SSC biology could facilitate the use of these cells in the context of fertility preservation of prepubertal children, as a key component of regenerative medicine.

31 March 2023
Verified
Other
Open access
LMLaetitia Mauge
Laetitia Mauge
AMArnaud Mejean
Arnaud Mejean
LFLaure Fournier
Laure Fournier
HPHelena Pereira
Helena Pereira
MEMarie-Christine Etienne-Grimaldi
Marie-Christine Etienne-Grimaldi
SOStéphane Oudard
Stéphane Oudard

31 March 2023
Verified
Other
Open access
LMLaetitia Mauge
Laetitia Mauge
AMArnaud Mejean
Arnaud Mejean
LFLaure Fournier
Laure Fournier
HPHelena Pereira
Helena Pereira
MEMarie-Christine Etienne-Grimaldi
Marie-Christine Etienne-Grimaldi
SOStéphane Oudard
Stéphane Oudard
Summary of currently available data looking at biomarkers during antiantiogenic therapy

31 March 2023
Verified
Other
Open access
LMLaetitia Mauge
Laetitia Mauge
AMArnaud Mejean
Arnaud Mejean
LFLaure Fournier
Laure Fournier
HPHelena Pereira
Helena Pereira
MEMarie-Christine Etienne-Grimaldi
Marie-Christine Etienne-Grimaldi
SOStéphane Oudard
Stéphane Oudard
Adverse events occurring in >10% of patients